Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy

Histone deacetylases (HDACs) regulate cardiac plasticity; however, their molecular targets are unknown. As autophagy contributes to pathological cardiac remodeling, we hypothesized that HDAC inhibitors target autophagy. The prototypical HDAC inhibitor (HDACi), trichostatin A (TSA), attenuated both load- and agonist-induced hypertrophic growth and abolished the associated activation of autophagy. Phenylephrine (PE)-triggered hypertrophy and autophagy in cultured cardiomyocytes were each blocked by a panel of structurally distinct HDAC inhibitors. RNAi-mediated knockdown of either Atg5 or Beclin 1, two essential autophagy effectors, was similarly capable of suppressing ligand-induced autophagy and myocyte growth. RNAi experiments uncovered the class I isoforms HDAC1 and HDAC2 as required for the autophagic response. To test the functional requirement of autophagic activation, we studied mice that overexpress Beclin 1 in cardiomyocytes. In these animals with a fourfold amplified autophagic response to TAC, TSA abolished TAC-induced increases in autophagy and blunted load-induced hypertrophy. Finally, we subjected animals with preexisting hypertrophy to HDACi, finding that ventricular mass reverted to near-normal levels and ventricular function normalized completely. Together, these data implicate autophagy as an obligatory element in pathological cardiac remodeling and point to HDAC1/2 as required effectors. Also, these data reveal autophagy as a previously unknown target of HDAC inhibitor therapy.

[1]  J. Molkentin,et al.  Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. , 2010, Circulation.

[2]  P. Marks The clinical development of histone deacetylase inhibitors as targeted anticancer drugs , 2010, Expert opinion on investigational drugs.

[3]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[4]  B. Rothermel,et al.  Autophagy in Hypertensive Heart Disease* , 2010, The Journal of Biological Chemistry.

[5]  Peng Huang,et al.  Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation , 2009, Journal of cellular and molecular medicine.

[6]  D. Metzger,et al.  Autophagy is required to maintain muscle mass. , 2009, Cell metabolism.

[7]  A. Lane,et al.  Histone deacetylase inhibitors in cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Arunima Sengupta,et al.  FoxO Transcription Factors Promote Autophagy in Cardiomyocytes* , 2009, The Journal of Biological Chemistry.

[9]  S. Haggarty,et al.  HDAC2 negatively regulates memory formation and synaptic plasticity , 2009, Nature.

[10]  J. Schisler,et al.  Build it up-Tear it down: protein quality control in the cardiac sarcomere. , 2008, Cardiovascular research.

[11]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[12]  B. Rothermel,et al.  Autophagy in load-induced heart disease. , 2008, Circulation research.

[13]  B. Rothermel,et al.  Autophagy in load-induced heart disease. , 2008, Circulation research.

[14]  J. Epstein,et al.  Histone deacetylase inhibition reduces myocardial ischemia‐reperfusion injury in mice , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  A. Baldwin,et al.  Proteasome inhibition promotes regression of left ventricular hypertrophy. , 2008, American journal of physiology. Heart and circulatory physiology.

[16]  G. Baumann,et al.  Suppression of Cardiomyocyte Hypertrophy by Inhibition of the Ubiquitin-Proteasome System , 2008, Hypertension.

[17]  C. Thompson,et al.  Autophagy: basic principles and relevance to disease. , 2008, Annual review of pathology.

[18]  Guido Kroemer,et al.  Autophagy in the Pathogenesis of Disease , 2008, Cell.

[19]  Dian J. Cao,et al.  Histone deacetylase inhibition in the treatment of heart disease , 2008 .

[20]  Dian J. Cao,et al.  Histone deacetylase inhibition in the treatment of heart disease , 2008, Expert opinion on drug safety.

[21]  E. Olson,et al.  Cardiac plasticity. , 2008, The New England journal of medicine.

[22]  Na Wang,et al.  FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases , 2007, Proceedings of the National Academy of Sciences.

[23]  N. Mizushima,et al.  Autophagy: process and function. , 2007, Genes & development.

[24]  G. D. De Meyer,et al.  Autophagy in cardiovascular disease. , 2007, Trends in molecular medicine.

[25]  Daniel J. Klionsky,et al.  Autophagy: from phenomenology to molecular understanding in less than a decade , 2007, Nature Reviews Molecular Cell Biology.

[26]  U. Koch,et al.  Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases , 2007, Proceedings of the National Academy of Sciences.

[27]  W. Wurst,et al.  Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. , 2007, Cancer research.

[28]  Xiaoxia Qi,et al.  Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. , 2007, Genes & development.

[29]  J. Richardson,et al.  Cardiac autophagy is a maladaptive response to hemodynamic stress. , 2007, The Journal of clinical investigation.

[30]  J. Cleveland,et al.  Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. , 2007, Blood.

[31]  S. Rodríguez-Enríquez,et al.  Selective degradation of mitochondria by mitophagy. , 2007, Archives of biochemistry and biophysics.

[32]  Yasushi Matsumura,et al.  The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress , 2007, Nature Medicine.

[33]  W. Wurst,et al.  Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity , 2007, Nature Medicine.

[34]  G. Evan,et al.  Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. , 2007, The Journal of clinical investigation.

[35]  S. Vatner,et al.  Activation of the Cardiac Proteasome During Pressure Overload Promotes Ventricular Hypertrophy , 2006, Circulation.

[36]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[37]  E. Olson,et al.  Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy , 2006, Circulation.

[38]  Y. Bang,et al.  Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.

[39]  M. Jeong,et al.  Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic Banding , 2005, Circulation.

[40]  K. Shimada,et al.  Genome-Wide Screening for Target Regions of Histone Deacetylases in Cardiomyocytes , 2005, Circulation research.

[41]  P. Marks,et al.  Apoptotic and autophagic cell death induced by histone deacetylase inhibitors , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Olson,et al.  Histone Deacetylases 5 and 9 Govern Responsiveness of the Heart to a Subset of Stress Signals and Play Redundant Roles in Heart Development , 2004, Molecular and Cellular Biology.

[43]  Daniel J Klionsky,et al.  Development by self-digestion: molecular mechanisms and biological functions of autophagy. , 2004, Developmental cell.

[44]  J. Epstein,et al.  Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. , 2003, The Journal of clinical investigation.

[45]  Chun Li Zhang,et al.  Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy , 2002, Cell.

[46]  D. O’Carroll,et al.  Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression , 2002, The EMBO journal.

[47]  T. Yao,et al.  Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10* , 2002, The Journal of Biological Chemistry.

[48]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[49]  T. Yao,et al.  Molecular cloning and characterization of a novel histone deacetylase HDAC 10 , 2001 .

[50]  E. Olson,et al.  Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Dimauro,et al.  Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease) , 2000, Nature.

[52]  R. Kerber,et al.  Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. , 2000, Circulation.